eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
4/2022
vol. 14
 
Share:
Send email
Share:
abstract:
Original paper

Sarcopenia does not limit overall survival after interstitial brachytherapy for breast cancer liver metastases

Maximilian Thormann
1
,
Franziska Heitmann
1
,
Christine March
1
,
Maciej Pech
1
,
Peter Hass
2
,
Alexey Surov
1
,
Robert Damm
1
,
Jazan Omari
1

  1. University Clinic for Radiology and Nuclear Medicine, University Hospital Magdeburg, Magdeburg, Germany
  2. Clinic for Radiation Oncology, University Hospital Magdeburg, Magdeburg, Germany
J Contemp Brachytherapy 2022; 14, 4: 364–369
DOI: https://doi.org/10.5114/jcb.2022.119515
Online publish date: 2022/08/31
View full text Get citation
 
Purpose
Sarcopenia has been identified as a prognostic marker of clinical outcomes in several diseases. However, the influence of sarcopenia on non-surgical local treatments in breast cancer liver metastases (BCLM) is unknown. Therefore, the purpose of this study was to assess the effect of sarcopenia among patients with BCLM undergoing interstitial brachytherapy (iBT). Aim of the study was to evaluate the influence of baseline computed tomography (CT) psoas body composition parameters, including psoas muscle area (PMA), psoas muscle index (PMI), muscle density, and skeletal muscle gauge (SMG) on clinical variables in patients undergoing image-guided iBT.

Material and methods
Computed tomography scans of patients undergoing iBT for BCLM from 2006-2017 were retrospectively analyzed. PMA, PMI, and SMG were measured on pre-treatment CT scans. Parameters were associated with overall survival using logistic regression analysis.

Results
Sixty patients were included in the analysis. 27 patients (45%) were considered sarcopenic. Median overall survival was 27 months (SD = 4.0 months). In univariate analysis, neither PMA (HR = 0.956, 95% CI: 0.855-1.068, p = 0.423), average density (HR = 1.028, 95% CI: 0.985-1.072, p = 0.207), PMI (HR = 0.951, 95% CI: 0.701-1.290, p = 0.746), nor SMG (HR = 1.002, 95% CI: 0.998-1.006, p = 0.440) were associated with overall survival. There was no influence of sarcopenia on OS (HR = 0.975, 95% CI: 0.532-1.787, p = 0.934).

Conclusions
Sarcopenia does not predict overall survival in patients undergoing iBT for BCLM. Interstitial BT may therefore be a suggested treatment option in sarcopenic patients with BCLM eligible for local ablation.

keywords:

sarcopenia, breast cancer, liver metastases, local treatment, interstitial brachytherapy, survival

  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.